1. Home
  2. SGMT vs TTEC Comparison

SGMT vs TTEC Comparison

Compare SGMT & TTEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGMT
  • TTEC
  • Stock Information
  • Founded
  • SGMT 2006
  • TTEC 1982
  • Country
  • SGMT United States
  • TTEC United States
  • Employees
  • SGMT N/A
  • TTEC N/A
  • Industry
  • SGMT
  • TTEC Retail: Computer Software & Peripheral Equipment
  • Sector
  • SGMT
  • TTEC Technology
  • Exchange
  • SGMT Nasdaq
  • TTEC Nasdaq
  • Market Cap
  • SGMT 159.0M
  • TTEC 190.4M
  • IPO Year
  • SGMT 2023
  • TTEC 1996
  • Fundamental
  • Price
  • SGMT $4.39
  • TTEC $3.97
  • Analyst Decision
  • SGMT Buy
  • TTEC Buy
  • Analyst Count
  • SGMT 6
  • TTEC 5
  • Target Price
  • SGMT $23.00
  • TTEC $11.17
  • AVG Volume (30 Days)
  • SGMT 1.2M
  • TTEC 328.9K
  • Earning Date
  • SGMT 11-13-2024
  • TTEC 02-27-2025
  • Dividend Yield
  • SGMT N/A
  • TTEC 1.51%
  • EPS Growth
  • SGMT N/A
  • TTEC N/A
  • EPS
  • SGMT N/A
  • TTEC N/A
  • Revenue
  • SGMT N/A
  • TTEC $2,266,331,000.00
  • Revenue This Year
  • SGMT N/A
  • TTEC N/A
  • Revenue Next Year
  • SGMT N/A
  • TTEC N/A
  • P/E Ratio
  • SGMT N/A
  • TTEC N/A
  • Revenue Growth
  • SGMT N/A
  • TTEC N/A
  • 52 Week Low
  • SGMT $2.39
  • TTEC $3.67
  • 52 Week High
  • SGMT $20.71
  • TTEC $22.66
  • Technical
  • Relative Strength Index (RSI)
  • SGMT 44.30
  • TTEC 29.52
  • Support Level
  • SGMT $4.06
  • TTEC $3.88
  • Resistance Level
  • SGMT $7.38
  • TTEC $4.18
  • Average True Range (ATR)
  • SGMT 0.63
  • TTEC 0.22
  • MACD
  • SGMT -0.11
  • TTEC -0.06
  • Stochastic Oscillator
  • SGMT 9.94
  • TTEC 9.30

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

About TTEC TTEC Holdings Inc.

TTEC Holdings Inc provides customer engagement management tools and services. The company operates through four operating segments that are organized into two groups, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and most of the sales are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.

Share on Social Networks: